REATA PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • January 4th, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
This Agreement (“Agreement”) is made and entered into as of the 23rd day of September, 2015, by and between Reata Pharmaceuticals, a Delaware corporation (the “Company”), and J. Warren Huff (“Indemnitee”).
EMPLOYMENT AGREEMENT by and between Reata Pharmaceuticals, Inc. and Keith W. Ward, Ph.D.Employment Agreement • January 4th, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Texas
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of the 23rd day September of 2015, by and between Reata Pharmaceuticals, Inc., a Delaware corporation (together with its successors and assigns permitted hereunder, the “Company”), and Keith W. Ward, Ph.D. (the “Executive”).
EXCLUSIVE LICENSE AGREEMENT between Reata Pharmaceuticals, Inc. and KU Center for Technology Commercialization, Inc.License Agreement • January 4th, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Kansas
THIS LICENSE Agreement (“Agreement”) is entered into this 26th day of September, 2014 by and between the KU CENTER FOR TECHNOLOGY COMMERCIALIZATION, INC, a Kansas non-profit § 501(c)(3) corporation, having its principal place of business at 3901 Rainbow Boulevard, Kansas City, Kansas 66160, hereinafter referred to as “KUCTC” or “Licensor,” and “REATA PHARMACEUTICALS, INC.” having its principal place of business at 2801 Gateway Drive, Suite 150, Irving, Texas 75063, hereinafter referred to as “Licensee.”
REATA PHARMACEUTICALS, INC. EIGHTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • January 4th, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Texas
This EIGHTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of the 6th day of December, 2011, by and among REATA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), the parties listed on the signature pages hereto, the Investors (as defined herein) listed on Schedule A hereto, University of Texas System (“UT System”), and the stockholders of the Company listed on Schedule B hereto (the “Other Stockholders”).
EXCLUSIVE LICENSE and SUPPLY AGREEMENT by and between REATA PHARMACEUTICALS, INC. and KYOWA HAKKO KIRIN CO. LTD.Supply Agreement • January 4th, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Exclusive License and Supply Agreement (this “Agreement”) effective as of December 24, 2009 (the “Effective Date”), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“Reata”), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan (“Kyowa Kirin”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”
LEASE SDCO GATEWAY COMMERCE I & II, INC., Landlord, and REATA PHARMACEUTICALS, INC., TenantCommencement Date Agreement • January 4th, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations
By this Lease Landlord leases to Tenant and Tenant leases from Landlord the Premises in the Building as set forth and described on the Reference Pages. The Premises are depicted on the floor plan attached hereto as Exhibit A, and the Building is depicted on the site plan attached hereto as Exhibit A-1. The Reference Pages, including all terms defined thereon, are incorporated as part of this Lease.
EXCLUSIVE PATENT LICENSE AGREEMENT AMONG THE UNIVERSITY OF TEXAS DARTMOUTH COLLEGE AND REATA DISCOVERY, INC.Patent License Agreement • January 4th, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Texas
THIS Agreement (“AGREEMENT”) is made on this 15th day of July, 2004, by and among the Board of Regents (the “BOARD”) of The University of Texas System (the “SYSTEM”), an agency of the State of Texas, whose address is 201West 7th Street, Austin, Texas 78701, on behalf of the University of Texas M. D. Anderson Cancer Center (‘‘UTMDACC”), a component institution of the SYSTEM, Trustees of Dartmouth College (“DARTMOUTH”), a non-profit educational and research institution existing under the laws of the State of New Hampshire, and being located at Hanover, New Hampshire (BOARD, UTMDACC and DARTMOUTH collectively “LICENSORS”), and Reata Discovery, Inc. (“LICENSEE”), a Delaware corporation having a principal place of business located at 1950 N. Stemmons Freeway, Suite 5001, Dallas, Texas 75207.
REATA PHARMACEUTICALS, INC. - DARTMOUTH EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • January 4th, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
TRUSTEES OF DARTMOUTH COLLEGE, a non-profit educational and research institution existing under the laws of the State of New Hampshire, and being located at Hanover, New Hampshire 03755, hereinafter called Dartmouth,
